Recursion Pharmaceuticals, Inc. RXRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$559.78M+13.2% | -$644.76M+9.9% | -$715.54M-10.2% | -$649.13M-12.9% | -$574.78M-24.0% | ||
| $84.04M+0.4% | $83.7M+8.5% | $77.17M+21.9% | $63.33M+30.7% | $48.45M+32.8% | ||
| $97.38M-12.4% | $111.22M-5.9% | $118.24M+6.3% | $111.25M+9.5% | $101.62M+24.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.5M— | ||
| —— | —— | $1.09M-80.1% | $5.46M-39.0% | $8.96M+39.2% | ||
| —— | —— | —— | —— | —— | ||
| -$43.68M-29.3% | -$33.78M-6.0% | -$31.88M-30.2% | -$24.48M— | —— | ||
| —— | —— | —— | -$31.94M-47.0% | -$21.72M-33.0% | ||
| -$29.26M+20.4% | -$36.77M-3.1% | -$35.68M— | —— | —— | ||
| -$320.95M+13.7% | -$371.81M+15.7% | -$441.17M-15.2% | -$383.03M+1.5% | -$388.83M-8.3% | ||
| $4.9M-24.3% | $6.47M-0.8% | $6.52M-39.8% | $10.84M+22.2% | $8.87M-35.2% | ||
| $2.81M-26.3% | $3.81M0.0% | $3.81M+154% | $1.5M+50.0% | $1M— | ||
| —— | —— | —— | —— | -$4.44M— | ||
| —— | —— | —— | $2.51M-25.1% | $3.35M0.0% | ||
| -$9.94M+41.1% | -$16.87M-106% | $259.83M+0.8% | $257.82M-0.6% | $259.44M-0.2% | ||
| $8.59M+1.9% | $8.43M+0.8% | $8.36M-1.9% | $8.52M+31.9% | $6.46M+45.5% | ||
| $487.84M-7.8% | $528.86M+30.1% | $406.51M+141% | $169.02M-48.9% | $330.57M+10.0% | ||
| $477.54M-8.4% | $521.53M+30.3% | $400.17M+142% | $165.29M-50.0% | $330.75M+8.8% | ||
| $9.38M-48.0% | $18.04M+44.5% | $12.49M+13.3% | $11.02M+569% | $1.65M+148% | ||
| $156.02M+3.4% | $150.9M-34.8% | $231.31M— | —— | —— | ||
| —— | —— | —— | —— | -$4.5M— | ||
| —— | —— | —— | —— | —— | ||
| -$18.88M+5.5% | -$19.99M+2.9% | -$20.59M-2.6% | -$20.07M-14.4% | -$17.55M-12.6% | ||
| —— | —— | —— | —— | —— | ||
| -$43.68M-29.3% | -$33.78M-6.0% | -$31.88M-30.2% | -$24.48M— | —— | ||
| -$22.73M+54.4% | -$49.86M-178% | -$17.91M— | —— | —— | ||
| —— | —— | —— | -$31.94M-47.0% | -$21.72M-33.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $2.51M-25.1% | $3.35M0.0% | ||
| —— | —— | —— | —— | -$4.44M— | ||
| —— | —— | —— | —— | —— | ||
| $8.59M+1.9% | $8.43M+0.8% | $8.36M-1.9% | $8.52M+31.9% | $6.46M+45.5% | ||
| —— | —— | —— | —— | —— | ||
| -$29.26M+20.4% | -$36.77M-3.1% | -$35.68M— | —— | —— | ||
| $1.92M— | $0-100% | $1.5M-50.0% | $3M-33.3% | $4.5M-25.0% | ||
| $21.36M-4.0% | $22.25M-1.0% | $22.48M-1.4% | $22.8M+12.4% | $20.27M+22.0% | ||
| —— | —— | —— | —— | —— | ||
| -$325.85M+13.9% | -$378.28M+15.5% | -$447.69M-13.7% | -$393.87M+1.0% | -$397.71M-6.7% | ||
| -$325.85M+13.9% | -$378.28M+15.5% | -$447.69M-13.7% | -$393.87M+1.0% | -$397.71M-6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Recursion Pharmaceuticals, Inc. generate?
- Recursion Pharmaceuticals, Inc. (RXRX) generated -$321.0M in operating cash flow over the trailing twelve months.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- After $4.9M of capital expenditures, Recursion Pharmaceuticals, Inc.'s free cash flow was -$325.8M over the trailing twelve months, up 18.1% year over year.
- Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
